IGC Pharma Receives Notice of Allowance for Patent on Seizures
June 06 2023 - 9:20AM
Business Wire
IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”),
today announced that it has received a Notice of Allowance from the
Commissioner of Patents, Canada, for its patent filing on the use
of cannabinoids in the treatment of seizures (IGC-501). The
formulation also received an intent to grant from the European
Patent Office. With these awards, and a previous one, the
formulation for treating seizures is protected in the U.S., Canada,
and certain European countries.
IGC provided animal data, with dogs, on the reduction in the
number of seizures by using a combination of cannabidiol (CBD) and
phenobarbital versus either alone. The Company intends to pursue
the combination in further trials with a view towards monetizing
the formulation as soon as practical. One potential market is dogs
in America. There are about 63.4 million dogs in the U.S. and
approximately, 1 in 20 may experience a seizure in their lifetime.
A seizure is a sudden surge in the electrical activity of the brain
that causes twitching, shaking, tremors, convulsions, and (or)
spasms. Seizures can last a few seconds to a few minutes. The
Company’s intellectual property includes over 40 filed patent
applications in various countries, including the U.S.
About IGC Pharma, Inc.
IGC Pharma (dba IGC) develops advanced cannabinoid-based
formulations for treating diseases and conditions, including, but
not limited to, Alzheimer’s disease, period cramps
(“dysmenorrhea”), premenstrual syndrome (“PMS”) and chronic pain.
IGC has two investigational drug assets targeting Alzheimer’s
disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s
cell lines the potential to be effective in suppressing or
ameliorating key hallmarks of Alzheimer’s disease, such as plaques
or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (“THC”)
based formulation that is currently in a 146-person Phase 2
clinical trial for agitation in dementia due to Alzheimer’s
(clinicaltrials.gov, NCT05543681). IGC also markets a wellness
brand, Holief™, that targets women experiencing premenstrual
syndrome and menstrual cramps. For more information visit
https://igcpharma.com/
Forward-looking
Statements
This press release contains forward-looking statements. These
forward-looking statements are based largely on IGC’s expectations
and are subject to several risks and uncertainties, certain of
which are beyond IGC’s control. Actual results could differ
materially from these forward-looking statements as a result of,
among other factors, the Company’s failure or inability to
commercialize one or more of the Company’s products or
technologies, including the products or formulations described in
this release, or failure to obtain regulatory approval for the
products or formulations, where required; general economic
conditions that are less favorable than expected, including as a
result of the ongoing COVID-19 pandemic; the FDA’s general position
regarding cannabis- and hemp-based products; and other factors,
many of which are discussed in IGC’s U.S. Securities and Exchange
Commission (“SEC”) filings. IGC incorporates by reference the human
trial disclosures and Risk Factors identified in its Annual Report
on Form 10-K filed with the SEC on June 23, 2022, as if fully
incorporated and restated herein. In light of these risks and
uncertainties, there can be no assurance that the forward-looking
information contained in this release will occur.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230606005269/en/
IMS Investor Relations Walter Frank igc@imsinvestorrelations.com
(203) 972-9200
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Apr 2024 to May 2024
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From May 2023 to May 2024